Rationale: Patients with mild chronic obstructive pulmonary disease (COPD) present abnormal ventilatory mechanics during exercise and may require bronchodilator therapy. However, bronchodilation does not enhance cycling exercise tolerance in these patients whereas walking may be more sensitive to the effects of bronchodilation. Objectives: To characterize the impact of bronchodilation on i) exercise tolerance ii) cardiopulmonary response and iii) dynamic hyperinflation following an endurance shuttle walking test in patients with mild COPD. Methods: In a randomized double-blind cross-over trial, 37 patients with GOLD stage I COPD (FEV 1 , 96 AE 2% predicted, mean AE SEM) completed an endurance shuttle walking test up to exhaustion 90 AE 15 min following nebulization of a placebo [NaCl] or of ipratropium bromide/salbutamol sulfate (500 mg/2.5 mg) combination. Results: FEV 1 significantly increased following bronchodilation compared with placebo (0.17 AE 0.02 vs. À0.02 AE 0.01 L, p < 0.0001, mean AE SEM). The difference in walking endurance time between bronchodilation and placebo was not statistically significant (D15 AE 12 s, p Z 0.21), with the upper and lower boundaries of the 95% confidence interval [À9e40 s, 95% CI] within the proposed minimally important difference for this variable (65 s). The ratio of breathing frequency to tidal volume tended to be decreased with bronchodilation during exercise (p Z 0.07), indicating a deeper and slower breathing pattern with bronchodilation. Bronchodilation had a significant effect on dynamic hyperinflation at isotime and at peak exercise. Conclusion: Bronchodilation did not improve walking endurance in patients with mild COPD despite small physiological benefits of uncertain clinical relevance. ª
Introduction
According to current treatment guidelines, patients with mild (GOLD stage I) chronic obstructive pulmonary disease (COPD) could be prescribed short-acting bronchodilators treatment to relieve symptoms if considered appropriate by the treating physician. 1e3 There is currently a paucity of data on the long-term safety and efficacy profiles of bronchodilator therapy in patients with mild COPD. 4e6 The few available studies nevertheless suggest that symptomatic mild COPD patients may benefit from bronchodilator therapy. 4, 7 Mild COPD patients may experience gas exchange impairments, 8 ventilatory inefficiency and dynamic hyperinflation during exercise, 5 together resulting in exercise intolerance. Bronchodilators play a pivotal role in improving exercise capacity in moderate to severe COPD, 9e14 but little is known regarding their exercise enhancing potential in mild COPD. A recent study evaluated the impact of ipratropium bromide on exercise response in symptomatic patients with GOLD stage I COPD. 4 Even though pulmonary function, operating lung volumes and dyspnea were improved, bronchodilation did not increase cycling endurance time. One potential explanation for this negative observation is that peripheral muscle fatigue, which is often seen during cycling, could have prevented bronchodilation to translate into better endurance time. 15 Indeed, cycling was found to be less sensitive than walking to detect changes in exercise performance after bronchodilation, partially because quadriceps muscle fatigue is more of an issue with this exercise modality than with walking.
14 Another appealing aspect of walking is that it also more representative of daily life activities than cycling. 16 We hypothesized that walking may be a well suited exercise testing modality to document possible improvement in exercise capacity following bronchodilation in patients with GOLD stage I COPD. Our general objective was to characterize the impact of short-acting bronchodilation on walking exercise tolerance in patients with GOLD stage I COPD. We therefore compared the i) endurance time ii) cardiopulmonary response and iii) dynamic hyperinflation during an endurance shuttle walking test (ESWT) in patients with mild COPD after either bronchodilation or placebo inhalation.
Methods

Ethics statement
The study was approved by the institutional ethics committee ( 18 Patients receiving bronchodilators before the beginning of the study were asked to withdraw from their medication 8 h in the case of short-acting bronchodilators and/or 72 h in the case of long-acting bronchodilators before the visits. Those treated with tiotropium had a 4-week washout period during which this therapy was replaced by ipratropium bromide.
Participants were recruited following their recent participation in COPD or lung cancer screening studies (n Z 30) or following consultation with a chest physician (n Z 7). Apart from the participation in screening studies, none of the participants were involved in previous research protocols. Subjects were excluded if they presented any medical condition, other than COPD, likely to influence muscle and exercise testing (i.e. cardiovascular, neurological, musculoskeletal, locomotor or other respiratory diseases as well as ß-blockers therapy). The flow chart of the study is presented in Fig. 1 . 19 Subjects were asked to avoid alcohol, caffeine and heavy meals 3 h before the visit and high intensity physical activity for at least 24 h before testing. Data reported were collected at the Institut Universitaire de cardiologie et de pneumologie de Québec. Experimental visits were conducted at the same time of the day for every subject.
Study design
This was a randomized, double blind, placebo-controlled and cross-over trial. Study participation included three distinct visits separated by !72 h and 7 days. During the first visit, anthropometric measurements, complete pulmonary function tests and symptom-limited incremental shuttle walking test (ISWT) were completed. During this visit, participants were also familiarized with the endurance shuttle walking test (ESWT) to minimize learning effects with this test. 20 In the subsequent two visits (Fig. 2 ), subjects entered a double-blind randomized cross-over design where an endurance shuttle walking test (ESWT) was performed up to exhaustion following either nebulized ipratropium bromide 500 mg and salbutamol sulfate 2.5 mg combination [Combivent
UDV
, Boehringer Ingelheim, Mississauga, Ontario, Canada] (BD) or nebulized isotonic sodium chloride (placebo, PL). Spirometry was performed at baseline and 60-min after nebulization. ESWT were performed 90 AE 15 min after nebulization. Prior to ESWT and 10-min post-exercise, quadriceps muscle force was quantified. A biostatistician determined the random allocation sequence of placebo and bronchodilator using a computer generated randomization list. Placebo and the active medication were prepared by the study pharmacist and had an identical appearance. Finally, the patients and the technician in charge of all the investigation were blinded from the experimental condition.
Pulmonary function testing
Spirometry, lung volumes and diffusion capacity (DL CO ) were obtained at baseline according to previously described guidelines 21 and related to predicted normal values. 22, 23 The predicted value for inspiratory capacity (IC) was obtained by subtracting the functional residual capacity (FRC) predicted value from total lung capacity (TLC) predicted value. The FEV 1 /FVC ratio was compared to the lower limit of the normal (LLN) range according to the NHANES III predicted values. 23 Reported values were measured after the inhalation of 400 mg of salbutamol in every participant. 24 Maximal voluntary ventilation (MVV) was estimated by multiplying FEV 1 by 35. 
Exercise testing Incremental shuttle walking test (ISWT)
A symptom-limited incremental shuttle walking test was realized in an enclosed corridor on a flat 10-m-long course. The original protocol previously validated in COPD 26 was adapted to include 3 additional walking cadences in order to allow every participant to reach symptom limitation. During the test, subjects wore a facemask, linked to a portable gas exchange analyzer (Oxycon Mobile, Viasys Healthcare, Jaeger, Germany). Ventilation ( _ V E ), oxygen consumption ( _ VO 2 ), CO 2 output ( _ VCO 2 ) and respiratory exchange ratio (RER) were monitored on a breath-bybreath basis. Oxygen pulse saturation (SpO 2 ) was measured at baseline and during exercise using a pulse oximeter (Nellcor N-395, Covidien, Boulder, CO, USA). Blood pressure was measured manually at baseline and at end-exercise. Dyspnea and leg fatigue Borg scores 27 were obtained at baseline and at end of exercise. A 12-lead electrocardiogram (Cardiosoft, Corina, Milwaukee, WI, USA) was used to monitor cardiac activity throughout exercise. Patients were allowed to run in order to attain maximal exercise capacity and standardized encouragements were provided to the patients.
Endurance shuttle walking test (ESWT)
The test was realized with the same setting as the ISWT. After a 90-sec warm-up phase, subjects were asked to follow a fixed cadence until exhaustion, corresponding to 85% of the predetermined _ VO 2peak , as predicted from incremental shuttle walking. The original protocol previously validated in moderate to severe COPD patients 28 was adapted to include 4 additional speed steps in order to allow every participant to reach symptom limitation with the ESWT. Patients were instructed to maintain the fixed cadence for as long as possible and standardized instructions were given during the test in order to avoid any potential effect on exercise performance. 29 Endurance time was defined as the duration of ESWT excluding the 90-s warm-up period. As for ISWT, patients were allowed to run to maintain the imposed cadence. Cardiorespiratory response was monitored using the same setup as for ISWT except that patients were asked to rate dyspnea and leg fatigue perception every minute during the test. Inspiratory capacity (IC) was measured at baseline, every 2-min during exercise and at peak exercise following previously described procedures. 30 
Quadriceps muscle function
Potentiated quadriceps twitch force (TwQ pot ) of the dominant leg was measured by supramaximal magnetic stimulation of the femoral nerve 3 s following an isometric maximal voluntary contraction of the quadriceps as previously reported. 31 Each maneuver was separated by 30 s. The reported values correspond to the mean of the three strongest contractions for TwQ pot . This was done in order to ensure that peripheral muscle fatigue did not represent a limiting factor to exercise. Quadriceps fatigue was defined as a post-exercise fall in TwQ pot > 15% resting value. 15 
Statistical analysis
All variables are expressed as means AE SEM. _ V E , _ VO 2 , _ VCO 2 , heart rate (HR), tidal volume (VT), breathing frequency (B f ), IC, SpO 2 and oxygen pulse (O 2 pulse) were compared at rest between the two conditions using a paired t-test. The time course of these parameters were also compared during exercise between the two experimental conditions using a mixed repeated analysis of variance (ANOVA). One hundred percent isotime was defined as the latest exercise time that was reached during the bronchodilation and placebo conditions. Before and after the ESWT, muscle force was compared using paired t-test. Pearson correlations were performed to examine the association between non-repeated measures. A statistical level of significance of 0.05 was used for all analysis. The data were analyzed using the statistical package program JMP (Version 8.0.1, SAS Institute Inc., Cary, NC ).
Since no data were available on the impact of bronchodilation on the endurance shuttle walking capacity in mild COPD, the study sample size calculation was based on the response in moderate to severe COPD patients 14 and the minimal important difference for this test previously reported by our group. 32 Accordingly, 45 patients were necessary to detect a 65 s difference in walking endurance between the two conditions with a SEM of change of 43 s (a Z 0.05 and 1 À b Z 0.80) in a cross-over trial. An interim analysis was planned when 75% of the calculated sample size was reached.
Results
Subjects
Thirty-seven patients with mild COPD were randomized; they all completed the study (Fig. 1) . The recruitment and testing period was from May 2009 and November 2010. We stopped recruiting after the blinded interim analysis revealed that the upper boundary of the 95% confidence interval around the difference in endurance time between the two experimental conditions was under the minimally significant difference for this variable. Characteristics of the participants are presented in Table 1 . Diffusing lung capacity was mildly reduced in these patients.
Spirometric response to bronchodilation
Spirometric values prior to nebulization at visit 2 and 3 were similar. The impacts of bronchodilation on resting pulmonary function are presented in Fig. 3 . The pre and post treatment difference in FEV 1 was significantly greater with active bronchodilation when compared with placebo (0.17 AE 0.02 vs. À0.02 AE 0.01 L, p < 0.0001, mean AE SEM). FVC and IC were not significantly modified by bronchodilation.
Twenty seven percent of mild COPD patients met the criteria defining a significant response to bronchodilation (BD) (FEV 1 ! 12% and !200 mL). 33 The average post-pre BD FEV 1 improvement in BD responders (n Z 10) was 0.34 AE 0.03 L compared to 0.11 AE 0.02 L (p < 0.001) in the BD non-responders (n Z 27). Similarly, the FVC increase after bronchodilation was significantly higher in BD responders than BD non-responders [DFVC (postepre BD), 0.28 AE 0.14 vs. À0.05 AE 0.05 L, p < 0.01]. The BD responders were characterized by a more altered pulmonary function and a more symptomatic profile as evidenced by a lower FEV 1 (88 AE 3 vs. 99 AE 2% pred., p < 0.01), FEV 1 / FVC (55 AE 2 vs. 64 AE 1%, p < 0.001), DL CO (70 AE 5 vs. 86 AE 3% pred., p < 0.05) and BDI score (7.8 AE 0.3 vs. 9.4 AE 0.3, p < 0.01).
Walking exercise endurance and bronchodilation
On average, bronchodilation did not significantly improve endurance time during endurance shuttle walking (230 AE 22 vs. 246 AE 22 s, during placebo and active bronchodilation, respectively) (Fig. 4, panel A) . The mean difference between the two treatments (BD-Placebo) was 15 AE 12 s (95% CI: À9e40 s) (Fig. 4, panel B) .
Physiological response to exercise
When comparing the impact of bronchodilation with placebo, we found no difference in _ VO 2 , _ VCO 2 , HR and O 2 pulse at the various timepoints ( Table 2 ). The fall in SpO 2 from baseline to peak exercise was significantly reduced with active bronchodilation when compared with placebo (À0.9 AE 0.4 vs. À2.2 AE 0.6%, p < 0.01).
Ventilatory and breathing pattern responses during walking are reported in Fig. 5 . We found no differences in the ventilatory response between the placebo and bronchodilation conditions. The ratio of breathing frequency to tidal volume (B f /V T ) tended to be decreased with bronchodilation over the exercise period (p Z 0.07), reflecting a deeper and slower breathing pattern with bronchodilation. Finally, _ V E /maximal voluntary ventilation (MVV) ratio was reduced with bronchodilation.
Inspiratory capacity values at rest and during exercise are shown in Fig. 5 . Inspiratory capacity tended to be higher after active bronchodilation than after placebo at rest (p Z 0.11); this difference amounting to 100 AE 80 mL reached statistical significance at isotime and endexercise. The fall in inspiratory capacity from rest to endexercise was similar for the two experimental conditions (0.59 AE 0.07 L vs. 0.58 AE 0.08 L).
Symptoms during exercise
No differences were found between bronchodilation and placebo conditions either on dyspnea and leg fatigue perceptions at isotime and at end-exercise (Fig. 5 , panel GeH ). The majority of patients stopped exercise because of dyspnea (73% and 68% in the placebo and active bronchodilation conditions, respectively).
Quadriceps muscle fatigue
The fall in TwQ pot occurring after ESWT were similar and within the variability of the measurements in both experimental conditions (À9 AE 1% and À8 AE 1% after the placebo and active bronchodilation conditions, respectively). Quadriceps fatigue developed in 8 patients (22% of the study population) after the placebo and/or bronchodilation conditions, respectively.
Predictors of improvement in walking endurance following bronchodilation
The extent of FEV 1 response to bronchodilation was heterogeneous (95% CI: 0.12e0.22 L). Ten patients met the criteria defining a significant response to bronchodilation (FEV 1 ! 12% and !200 mL). 33 These patients did not exhibit a larger improvement in walking endurance time when compared to those who did not respond to bronchodilation [D endurance time (bronchodilationeplacebo) Z 26 AE 21 vs. 12 AE 15 s for the bronchodilator responders and nonresponders, respectively, p Z 0.61]. A larger fall in inspiratory capacity from rest to peak exercise, expressed in % predicted or in L, was associated with a larger improvement in walking endurance time with bronchodilation [R Z À0.35, p < 0.05 (for IC % predicted); R Z À0.40, 
Discussion
The present study investigated for the first time the impact of bronchodilation on walking exercise tolerance in patients with mild COPD. The main findings of this study were that, in patients with mild COPD, acute bronchodilation had modest physiological benefits during walking including reduced operating lung volumes and a tendency for improved breathing pattern. However, these physiological benefits did not translate into better walking endurance nor decreased dyspnea intensity during walking.
Impact of bronchodilation on walking endurance
In contrast to our initial hypothesis, we found that bronchodilation did not significantly improve walking exercise tolerance, even if this exercise modality may be more sensitive than cycling to detect changes in exercise tolerance after bronchodilation in COPD 14 and induces much less fatigue of the legs than cycling.
14, 34 The observation of a slight post-exercise reduction in the quadriceps twitch force that was within the fatigue threshold for the whole group and that only 22% of the study population developed quadriceps fatigue, as compared to 50e60% during cycling, 14 is consistent with this last notion. 15 The 95% confidence interval around the mean difference in walking endurance time between bronchodilation and placebo crossed zero and was within the suggested minimally significant threshold for this variable (65 s). 32 We can thus conclude from this finding that acute bronchodilation did not significantly improve walking endurance both from a statistical and clinical standpoint. One patient dramatically decreased endurance time with bronchodilation (À240 s). When excluding this patient from the analysis, the difference in walking endurance between the two treatments reached statistical significance (23 AE 10 s [95% CI: 2e43 s], p Z 0.03] but the upper boundary of the 95% CI of the difference was still smaller than 65 s. As such, the conclusion about the inability of acute bronchodilation to improve waking capacity beyond the minimally significant threshold in patients with mild COPD remained unchanged. This finding is consistent with a previous report showing that acute bronchodilation did not enhance cycling endurance in mild COPD. 4 We considered the possibility that the absence of improvement in exercise capacity could be related to a suboptimal bronchodilation response. The absolute improvement in FEV 1 (170 mL) was comparable to what was seen in previous trials demonstrating an improved walking capacity after the administration of a single dose of ipratropium bromide (180e190 mL) in patients with moderate to severe COPD. 14, 20 However, when expressing this response in % baseline FEV 1 , the magnitude of improvement was much smaller in the present study (6%) than in previous studies (12e14%). 14, 20 The likelihood that such a small relative change in FEV 1 translates into meaningful gains in walking endurance appears to be small, particularly when expiratory flows are well preserved, such as in mild COPD.
Response to bronchodilator therapy may be underestimated when solely looking at spirometric parameters as hyperinflation and gas trapping can be improved with bronchodilation despite little or no change in FEV 1 . 35 Similarly to a previous investigation conducted in mild COPD, 4 inspiratory capacity was not improved following bronchodilation, suggesting that a reduction in resting lung volumes did not occur in our patients. This finding is expected when considering the normal baseline inspiratory capacity and lung volumes in our study population. This situation contrasts with previous studies confirming the possibility to enhance exercise capacity with bronchodilation in moderate to severe COPD in whom static hyperinflation (FRC ! 120% predicted) was a prerequisite for participation.
9e12 Considering that reducing operating lung volume during exercise is a key determinant of the exercise response to bronchodilation, the low levels of static hyperinflation in our patients could be partly responsible for the lack of improvement in exercise following bronchodilation.
The small physiological improvements that were observed during exercise with bronchodilation were entirely consistent with the expected benefits of this class of pharmacological agents. 11, 36, 37 They were also consistent in direction and magnitude to what was reported in a similar investigation of bronchodilation during cycling exercise in patients with GOLD I COPD. 4 Among the physiological improvements seen with therapy, there was a slight reduction in dynamic hyperinflation at isotime indicating that patients were breathing at lower lung volumes. 37 As expected from bronchodilators, 10, 11 this small reduction in dynamic hyperinflation was mainly a reflection of lung deflation at rest with bronchodilators since the slope of the fall in inspiratory capacity over time was not modified with therapy. In this context, the tendency for a slower and deeper breathing pattern was likely related to reduced mechanical constraint and operating lung volumes during exercise. 37 The ventilatory reserve was also improved with bronchodilation, a direct consequence of an improved FEV 1 since ventilation was unchanged with therapy.
The clinical relevance of these physiological improvements with bronchodilation remain uncertain because they did not translate into better walking endurance nor in reduced dyspnea perception. In fact, these physiological changes were likely too small to translate into clinical benefits. For example, in patients with GOLD IIeIII COPD, reductions in inspiratory capacity at isotime in the order of 200 mL (about twice as much as was is found in GOLD I) have been associated with reduced exertional dyspnea and prolonged exercise endurance. 10, 11 Interestingly, the observation that patients experiencing the largest fall in inspiratory capacity during exercise were the most likely to improve walking capacity following bronchodilation suggests that a more severe degree of hyperinflation at baseline could have been associated with a greater exercise response to bronchodilation.
Methodological considerations
We used the GOLD classification to stratify our patients because of its wide clinical application. This classification could lead to potential misdiagnosis, especially in elderly patients. 38 To address this potential limitation, we also stratified our cohort according to the FEV 1 /FVC lower limit of the normal and found that bronchodilation did not increase walking endurance, inspiratory capacity, nor improved exercise physiological response even when considering only those patients with an FEV 1 /FVC < lower limit of the normal (n Z 29).
Compared to stationary cycling exercise, measuring symptom perception and dynamic hyperinflation is more challenging during walking. However, we are confident that our measurements were reliable. Patients were familiarized with all study procedures. Measurements of inspiratory capacity were done with direct inspection of the flow/ volume loops and only measurements that were performed with optimal inspiratory efforts when a stable endexpiratory volume could be established were considered for analysis. We acknowledge that complete pulmonary function tests, including lung volume measurements, could have been useful to further document the impact of bronchodilation on lung hyperinflation in our patients. Lastly, this study does not exclude the possibility that more potent and/ or longer duration of bronchodilation could be associated with larger improvement in exercise capacity in mild COPD.
In conclusion, bronchodilation did not improve walking endurance in patients with mild COPD during walking exercise despite small beneficial effects on dynamic hyperinflation and breathing pattern during exercise.
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